We report an hemodialysis MDR HIV-infected patient switched to
fostemsavir with lenacapavir plus lamivudine for more than a year. She
maintained a suppressed viral replication and didn't present any
clinical or biological drug-related side effects. The combination of
lenacapavir plus fostemsavir looks promising in terms of safety and
efficacy even in patients with end-stage renal disease awaiting renal
transplant. Both drugs are first in class ARVs so that there is no cross
resistance with previous drugs, maintaining their efficacy against MDR
HIV.